• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2015 Fiscal Year Final Research Report

Resistance mechanisms to molecular targeted drugs in lung adenocarcinoma

Research Project

  • PDF
Project/Area Number 25710015
Research Category

Grant-in-Aid for Young Scientists (A)

Allocation TypePartial Multi-year Fund
Research Field Tumor therapeutics
Research InstitutionJapanese Foundation for Cancer Research

Principal Investigator

Katayama Ryohei  公益財団法人がん研究会, その他部局等, 主任研究員 (60435542)

Co-Investigator(Renkei-kenkyūsha) NISHIO Makoto  公益財団法人がん研究会, 有明病院・呼吸器内科, 部長 (00281593)
YANAGITANI Noriko  公益財団法人がん研究会, 有明病院・呼吸器内科, 医長 (60400785)
KITAZONO Satoru  公益財団法人がん研究会, 有明病院・呼吸器内科, 副医長 (90527863)
Project Period (FY) 2013-04-01 – 2016-03-31
Keywords分子標的薬 / 獲得耐性 / 変異 / チロシンキナーゼ阻害薬
Outline of Final Research Achievements

Non-small cell lung cancer (NSCLC) harboring driver oncogene such as EGFR mutation, ALK-, ROS1-, rearrangements are exquisitely sensitive to small molecule tyrosine kinase inhibitors (TKIs). Although most these driver oncogene positive NSCLC marketly respond to the corresponding TKIs, cancers inevitably develop resistance within a few years by the multiple mechanisms. We explored the resistance mechanisms to TKIs using cell line models and the patient derived specimens. As the results, we succeded to identify and reported various TKI resistance mechanisms in ALK, ROS1 or other driver oncogene positive NSCLC, such as multiple secondary mutations in the kinase domain, bypass pathway activation, or P-glycoprotein overexpression mediated resistance. We also found the potential therapeutic strategies to overcome the resistances. Our study potentially could serve as a framework for selecting and prioritizing therapeutic strategy in the clinic.

Free Research Field

腫瘍治療学

URL: 

Published: 2017-05-10  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi